TP53 and non-small cell lung carcinoma: While NSCLC patients with high TMB, mutated TP53, and LCAMhi profile with SPP1+ Macs (next to PD1+ CXCL13+ T cells, IgG+ plasma cells) showed superior responses, the opposite held true for patients with low TMB, TP53 wild type and LCAMlo profile characterized by mregDCs and PPARg+ Macs (next to naïve and central memory T cells and reduced plasma/B cell ratios).